Loading...
This record has been deleted. Since it is linked to a published record, it is available here for reference purposes only.
Click here to view the deleted recordThis document has been updated. This is not the latest published version. Click here to view the latest version of the record.
Risk Assessment generated by a regulatory process
(RA)
last updated: 16 Jun 2020
Summary risk assessment report on the application for Confined Field Trial of a novel Rift Valley Fever Vaccine in sheep, goats, cattle and camels
EN
25 Nov 2016
-
Competent National Authority:National Biosafety Authority ()NACOSTI Building, Loresho, off Waiyaki WayNairobi, Nairobi
28251--00100, KenyaPhone: (+254) (20) (2678667),Fax:Email: info@biosafetykenya.go.ke,Website: https://www.biosafetykenya.go.ke/,
-
Rift Valley Fever Virus DIVA vaccine| International Livestock Research Institute (ILRI) /The Jenner Institute, University of Oxford, United Kingdom | Production of medical or pharmaceutical compounds (human or animal) (Vaccines)
- Risk assessment summary for RFV Vaccine.pdf [ English ]
EN
| Record type | Field | Record(s) | |
|---|---|---|---|
| Country's Decision or any other Communication | Risk assessment | 1 | |
